Publication:
Colchicine in recently hospitalized patients with COVID-19: A randomized controlled trial (COL-COVID)

Simple item page
dc.contributor.authorPascual-Figal, Domingo A.
dc.contributor.authorRoura-Piloto, Aychel E.
dc.contributor.authorMoral-Escudero, Encarnación
dc.contributor.authorBernal, Enrique
dc.contributor.authorAlbendín-Iglesias, Helena
dc.contributor.authorPérez-Martínez, M. Teresa
dc.contributor.authorNoguera-Velasco, José Antonio
dc.contributor.authorCebreiros-López, Iria
dc.contributor.authorHernández-Vicente, Álvaro
dc.contributor.authorVázquez-Andrés, David
dc.contributor.authorSánchez-Pérez, Carmen
dc.contributor.authorKhan, Amjad
dc.contributor.authorSánchez-Cabo, Fátima
dc.contributor.authorGarcía-Vázquez, Elisa
dc.contributor.departmentMedicina
dc.date.accessioned2024-06-19T10:36:49Z
dc.date.available2024-06-19T10:36:49Z
dc.date.issued2021-09-11
dc.description©2021. Pascual-Figal et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). This document is the Published, version of a Published Work that appeared in final form in International Journal of General Medicine . To access the final edited and published work see https://doi.org/10.2147/IJGM.S329810es
dc.description.abstractBackground: Colchicine has been proposed as a potential therapy in coronavirus disease 2019 (COVID-19) due to their anti-inflammatory actions. Methods: The COL-COVID study was a prospective, randomized, controlled and openlabel clinical trial that compared colchicine added to standard treatment vs standard treatment in hospitalized COVID-19 patients that do not need mechanical ventilatory support. Colchicine was initiated within the first 48 hours of admission at a 1.5 mg loading dose, followed by 0.5 mg b.i.d. for one week and 0.5 mg per day for 28 days. The study endpoints were clinical status (7-points WHO ordinal scale) and inflammatory biomarkers (IL-6 and CRP). Results: A total of 103 patients (51±12 years, 52% male) were randomly allocated to colchicine arm (n=52) and control arm (n=51). At day 28, all patients in the colchicine group were alive and discharged, whereas in the control group, two patients died in-hospital and one patient remained hospitalized. Clinical improvement in terms of changes on WHO scale at day 14 and 28 and time to 1-point clinical improvement did not differ between the two groups. Clinical deterioration (increase of at least 1-point in WHO scale) was observed in a higher proportion of cases in colchicine group (13.8%) vs control group (5.8%) (p=0.303); after adjustment by baseline risk factors and concomitant therapies, colchicine therapy was associated with a lower risk of clinical deterioration (p=0.030). Inflammatory biomarkers CRP and IL-6 concentrations course did not differ between the two arms. Conclusion: In hospitalized COVID-19 patients, colchicine treatment neither improved the clinical status, nor the inflammatory response, over the standard treatment. Nevertheless, a preventive effect for further clinical deterioration might be possible.es
dc.formatapplication/pdfes
dc.format.extent10es
dc.identifier.doihttps: //doi.org/10.2147/IJGM.S329810
dc.identifier.eisbnInternational Journal of General Medicine 2021:14 5517–5526es
dc.identifier.issnElectronic: 1178-7074
dc.identifier.urihttp://hdl.handle.net/10201/142440
dc.languageenges
dc.publisherTaylor and Francis Group; Dove Medical Press Limitedes
dc.relationBiobank Network of the Region of Murcia, BIOBANC-MUR, registered on the Registro Nacional de Biobancos with registration number B.0000859. BIOBANC-MUR is supported by “Instituto de Salud Carlos III (proyecto PT20/00109) and “Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca, IMIB”es
dc.relation.publisherversionhttps://www.dovepress.com/colchicine-in-recently-hospitalized-patients-with-covid-19-a-randomize-peer-reviewed-fulltext-article-IJGMes
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectColchicinees
dc.subjectCOVID-19es
dc.subjectInflammationes
dc.titleColchicine in recently hospitalized patients with COVID-19: A randomized controlled trial (COL-COVID)es
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Colchicine in Recently Hospitalized Patients...pdf
Size:
742.25 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos